RATIONALE: Aerobic exercise may help prevent side effects caused by chemotherapy and help improve heart health.
PURPOSE: This randomized clinical trial is studying the side effects of aerobic exercise and to see how well it works in patients receiving chemotherapy for cancer.
Primary Outcome Measures:
- Percentage of patients enrolling in the study [ Designated as safety issue: No ]
- Percentage of patients completing the study [ Designated as safety issue: No ]
- Number and types of adverse events [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- V02 peak before and after chemotherapy [ Designated as safety issue: No ]
| Estimated Enrollment: |
28 |
| Study Start Date: |
June 2008 |
| Estimated Primary Completion Date: |
July 2009 (Final data collection date for primary outcome measure) |
OBJECTIVES:
- To determine if patients with cancer can exercise safely and routinely, under supervision, while receiving anthracycline chemotherapy.
- To determine the magnitude of the change in the peak ventilatory oxygen uptake (VO2) before and after completion of anthracycline chemotherapy with concurrent exercise versus without exercise in patients with cancer.
OUTLINE: Patients are randomized to 1 of 2 intervention arms.
- Arm I (exercise): Patients undergo supervised aerobic exercise (walk or bicycle) 3 days a week concurrently with standard anthracycline-based chemotherapy for approximately 18-24 weeks.
- Arm II (non-exercise): Patients receive standard anthracycline-based chemotherapy for approximately 18-24 weeks.
Patients undergo peak ventilatory oxygen uptake (VO_2) by exercise bike test with gas exchange analysis at baseline and at 2 weeks after completion of anthracycline-based chemotherapy.
Purpose
